Nanosphere snags $30.2M in stock sale

Nanosphere markets the FDA-cleared Verigene Gram-Positive Blood Culture Test.--Courtesy of Nanosphere

Diagnostics outfit Nanosphere ($NSPH) hauled in $30.2 million in an over-allotted stock sale, padding its war chest as it develops tests using gold nanoparticle chemistry.

Net of costs, Nanosphere will take home about $27.7 million through the offering, $3.6 million more than it expected thanks to its underwriters exercising their over-allotment options in full.

The raise gives Nanosphere a nice cash padding as it works to expand the adoption of its FDA-cleared Verigene Gram-Positive Blood Culture Test, an in vitro diagnostic designed to detect common bloodstream infections.

The company is also working toward agency sign-offs for its pipeline tests, planning a third-quarter FDA submission for its gram-negative blood stream infection panel and a fourth-quarter application for its gastrointestinal enteric offering. 

Each of the tests operates on Nanosphere's banner Verigene system, a platform that maps the genome of bacteria and uses gold nanoparticles to generate high-specificity results, the company said.

Last quarter, the company grew its revenue 38% to $1.9 million but slashed its full-year projections by about 25% "to better reflect the extensive implementation process that our customers utilize" after buying the Verigene blood test, CEO Michael McGarrity said in a statement.

- read Nanosphere's announcement

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.